PROFILPELAJAR.COM

MW073

MW073
Clinical data
Other namesMW-073
Drug classSerotonin 5-HT2B receptor antagonist
ATC code
  • None
Identifiers
  • 4-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-6-naphthalen-2-ylpyridazin-3-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H27N5
Molar mass361.493 g·mol−1
3D model (JSmol)
  • CC1=CC(=NN=C1NCCN2CCN(CC2)C)C3=CC4=CC=CC=C4C=C3
  • InChI=1S/C22H27N5/c1-17-15-21(20-8-7-18-5-3-4-6-19(18)16-20)24-25-22(17)23-9-10-27-13-11-26(2)12-14-27/h3-8,15-16H,9-14H2,1-2H3,(H,23,25)
  • Key:IBOOAZHRKKSRLF-UHFFFAOYSA-N

MW073 is a serotonin 5-HT2B receptor antagonist which is used in scientific research.[1][2][3][4][5] It is a highly selective antagonist of the serotonin 5-HT2B receptor.[3][2] The drug is orally active in animals and is said to have a favorable drug-like profile.[3][2] It produces antiaggressive effects without causing sedation or altering locomotor activity or anxiety in an animal model of Alzheimer's disease.[3][2] Similarly, it produces neuroprotective, neurorestorative, and pro-cognitive-like effects in such models.[3][2][5] MW073 was first described in the scientific literature by 2024.[4][2][3][5] There is interest in MW073 for the potential treatment of Alzheimer's disease and other conditions.[3][2]

See also

References

  1. ^ "Delving into the Latest Updates on MW073 with Synapse". Synapse. 9 May 2026. Retrieved 9 June 2026.
  2. ^ a b c d e f g Roy SM, Acquarone E, Argyrousi EK, Zhang H, Staniszewski A, Inoue A, et al. (2025). "Optimized 5-HT2b inhibitors for neuropsychiatric syndromes with cognitive dysfunction". Alzheimer's & Dementia. 11 (1) e70073. New York, N. Y. doi:10.1002/trc2.70073. PMC 11947739. PMID 40151398.
  3. ^ a b c d e f g Acquarone E, Roy SM, Staniszewski A, Watterson DM, Arancio O (February 2026). "The Highly Selective 5-HT2B Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse Model". Cells. 15 (3). doi:10.3390/cells15030273. PMC 12896383. PMID 41677635.
  4. ^ a b Acquarone E, Argyrousi EK, Arancio O, Watterson DM, Roy SM (2024). "The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction". Journal of Alzheimer's Disease. 98 (4): 1349–1360. doi:10.3233/JAD-240063. PMC 11091653. PMID 38578894.
  5. ^ a b c Roy S, Acquarone E, Ziarek JJ, Ottavio A, Watterson DM (2026). "MW073 Treatment Attenuates Synaptic Dysfunction, Cognition-Related Behavior Deficits, and Aggression in Alzheimer's Disease Models (Abstract ID: 273213)". The Journal of Pharmacology and Experimental Therapeutics. 393 (5) 104835. doi:10.1016/j.jpet.2026.104835.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.